Parvovirus B19: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
Line 18: Line 18:
<ref name=Rink>[https://www.mdpi.com/2218-273X/11/4/606. Rinkūnaitė, I., Šimoliūnas, E., Bironaitė, D., Rutkienė, R., Bukelskienė, V., Meškys, R., and Bogomolovas, J. "The Effect of a Unique Region of Parvovirus B19 Capsid Protein VP1 on Endothelial Cells" 2021. Biomolecules, 11(4), 606.]</ref>
<ref name=Rink>[https://www.mdpi.com/2218-273X/11/4/606. Rinkūnaitė, I., Šimoliūnas, E., Bironaitė, D., Rutkienė, R., Bukelskienė, V., Meškys, R., and Bogomolovas, J. "The Effect of a Unique Region of Parvovirus B19 Capsid Protein VP1 on Endothelial Cells" 2021. Biomolecules, 11(4), 606.]</ref>


==Genome Structure==
==Section 2==
The <i>Parvovirus</i> genome is a single strand of DNA with 5,596 nucleotides, 4,830 of which are coding regions.<ref name=ncbi/> This region contains 2 large open reading frames.<ref name=ncbi/> One large non-structural protein is coded by one open reading frame, NS1, and the second reading frame codes for 2 capsid proteins, VP1 and VP2.<ref name=ncbi/> The sequences of B19V isolates do not exhibit much genetic variation with NS1 showing incredibly high conservation, and 2-3% divergence in VP1 and VP2 regions.<ref name=ncbi/> When examining isolates from patients with chronic infection due to B19V, there is a much higher degree of variation at DNA and protein levels.<ref name=Hemauer/>
 
There are now 3 distinct genotypes recognized as <i>Parvovirus B19</i> including: (1) all prototype B19V isolates, (2) A6 and LaLi isolates, and (3) V9 and related isolates.<ref name=Chen/> These variations in the genome are potentially responsible for the variety of host responses to infection.<ref name=Chen/> In a study on 3 isolates of the 3 genotypes, the A6 isolate did not produce R5, R7, and R9 mRNAs, which are important in the production of VP1 and VP2 as coordinating mRNAs.<ref name=Chen/> There was also an increase in sequence divergence between the 3 isolates. They found that B19V NS1-V9 and B19V NS1-A6 diverge by 13% from B19V NS1, but only diverge by 6% in protein structure.<ref name=Chen/>
 
[[Image:Screenshot_2024-04-06_at_4.00.04_PM.png|thumb|300px|right| The V9 (A) and A6 (B) genomes are depicted with transcriptional landmarks. These include promoters (ie. P6), splice donors (D), and splice acceptors (A), as well as the ORFs encoded and their predicted protein sizes in kDa. Photo credit: [https://www-sciencedirect-com.libproxy.kenyon.edu/science/article/pii/S0042682209005303?via%3Dihub]]]


==Section 3==
==Section 3==

Revision as of 20:11, 6 April 2024

Background

The life cycle of Canine Parvovirus. Photo credit: [1]

By Grace Potter

Parvovirus B19 is the only member of the Parvoviridae family that has been found to infect human hosts.[1] It was discovered in 1974, when a research group looking at hepatitis B surface antigens found a serum sample with unexpected results.[1] Another lab in Japan described a similar virus in 1979 that they called "Nakatami".[1] When compared, the two were found to be identical.[1] In 1985 this virus was officially recognized as a member of the Parvoviridae family due to its similarities in genome size and density.[1]

Infection by Parvovirus B19 (Parvo B19V) causes many diseases, including "fifth disease" in children, aplastic crisis for people with hemolytic anemia, anemia in immunocompromised patients, acute or chronic arthropathy in adults, and fetal hydrops in pregnant women.[2][3] Changes in the genome are potentially responsible for the wide variation of clinical presentations associated with B19V infection.[2]

Section 1

Include some current research, with at least one figure showing data.

Parvoviridae

[4]

[5]

[6]

Section 2

Section 3

Include some current research, with at least one figure showing data.

Section 4

Conclusion

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Heegaard, E.D. and Brown, K.E. "Human Parvovirus B19." 2002. Clinical Microbiology Review 15(3):485-505.
  2. ↑ 2.0 2.1 Chen, Z., Guan, W., Cheng, F., Chen, A.Y., and Qiu, J. "Molecular characterization of human parvovirus B19 genotypes 2 and 3" 2009. Virology, 394(2), 276-285.
  3. ↑ Hemauer, A., von Poblotzki, A., Gigler, A., Cassinotti, P., Siegl, G., Wolf, H., and Modrow, S. "Sequence variability among different parvovirus B19 isolates" 1996. Journal of General Virology, 77(8), 1781-1785.
  4. ↑ Jalali, Sedigheh, Farhardi, Ali, Dehbidi, G.R., Farjadian, Shirin, Sharifzadeh, Sedigheh, Ranjbaran, Reza, Seyyedi, Noorossadat, Namdari, Sepide and Behzad-Behbahani, Abbas. "The Pathogenic Aspects of Human Parvovirus B19 NS1 Protein in Chronic and Inflammatory Diseases" 2022. Interdisciplinary Perspectives on Infectious Diseases.
  5. ↑ Ros, Carlos, Bieri, Jan, and Leisi, Remo. "The VP1u of Human Parvovirus B19: A Multifunctional Capsid Protein with Biotechnological Applications" 2020. Viruses, 12(12), 1463.
  6. ↑ Rinkūnaitė, I., Šimoliūnas, E., Bironaitė, D., Rutkienė, R., Bukelskienė, V., Meškys, R., and Bogomolovas, J. "The Effect of a Unique Region of Parvovirus B19 Capsid Protein VP1 on Endothelial Cells" 2021. Biomolecules, 11(4), 606.



Authored for BIOL 238 Microbiology, taught by Joan Slonczewski,at Kenyon College,2024

Retrieved from "https://microbewiki.kenyon.edu/index.php?title=Parvovirus_B19&oldid=164537"